XML 9 R2.htm IDEA: XBRL DOCUMENT v3.25.3
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Sep. 30, 2025
Dec. 31, 2024
Current assets:    
Cash and cash equivalents $ 40,402 $ 11,813
Short-term bank deposits 19,647 14,858
Notes receivable 693 4,373
Accounts receivable, net 25,877 19,589
Inventories 8,854 6,337
Prepaid assets and other current assets 2,873 2,625
Total current assets 98,576 64,786
Property and equipment, net 23,608 23,880
Intangible assets, net 4,847 273
Deferred tax assets 6,714 5,619
Long-term certificates of deposit 20,317 24,568
Other assets, noncurrent 5,322 6,280
Total assets 159,384 125,406
Current liabilities:    
Accounts payable 556 108
Contract liabilities 58 61
Due to related parties 228 227
Accrued expenses and other current liabilities 11,799 10,615
Income tax payable 2,646 2,831
Operating lease liabilities, current 626 713
CVR derivative liability 0 4,961
Total current liabilities 15,913 19,516
Operating lease liabilities, noncurrent 539 885
Deferred government grants 866 928
Warrant liability, noncurrent 3,224 5,668
Other noncurrent liabilities 1,427 7
Total liabilities 21,969 27,004
Commitments and Contingencies (Note 12)
Stockholders' equity:    
Common stock, $0.001 par value, 400,000,000 shares authorized; 90,890,381 shares and 86,307,544 shares issued and outstanding at September 30, 2025 and December 31, 2024, respectively 91 86
Additional paid-in capital 167,134 136,185
Statutory reserve 3,098 3,098
Accumulated deficit (66,703) (73,453)
Accumulated other comprehensive loss (1,700) (2,597)
Total Gyre stockholders' equity 101,920 63,319
Noncontrolling interest 35,495 35,083
Total equity 137,415 98,402
Total liabilities and stockholders' equity 159,384 125,406
GC Biopharma Corp    
Current assets:    
Receivable from GCBP 0 4,961
GNI    
Current assets:    
Other receivables from GNI $ 230 $ 230